Act4Biosimilars, a global biosimilar advocacy initiative, aims to increase global adoption of biosimilars by at least 30 percentage points in over 30 countries by 2030.
Here’s what you need to know:
- Regulatory and policy hurdles and varied market dynamics cause disparities in biosimilar uptake. Western European countries lead in adoption while developing nations, including Africa and Latin America, lag.
- Diverse healthcare systems and regulatory pathways require unique, local knowledge to navigate; hence, Act4Biosimilars’ strategy is to empower people with country-specific expertise to support governments in implementing changes.
- Within Latin America, policy obstacles and health infrastructure issues limit biosimilars’ potential. More significant effort is needed to start and expand education about biosimilars among healthcare professionals and patients.
- Act4Biosimilars launched an Action Plan that identifies challenges and opportunities to increase biosimilar adoption considering four key areas: Approvability, Acceptability, Accessibility, and Affordability.
- The Action Plan starts in the Americas, then expands to Europe in Q4 2023, the Middle East and Africa in Q1 2024, and Asia Pacific in Q2 2024.
- Act4Biosimilars will track the progress of the Action Plan via an Impact Index using metrics reflecting biosimilar adoption at global and country-level, which will be updated every two years.
- The target is a minimum of 44% biosimilar adoption by 2030.
- With more reference biologics upon losing exclusivity rights, more biosimilars will become available across a broader range of therapeutic areas, which is expected to improve healthcare quality and sustainability. Increasing access to these biosimilars to the global patient population is crucial.
To read more, click here.
[Source: Pharmaceutical Technology, August 9th, 2023]